Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by UNC Lineberger Comprehensive Cancer Center.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00577694
First received: December 19, 2007
Last updated: August 28, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2012
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)